Nov 2026· Frontiers in Immunology· 0 citations· 56 references
TL;DR
Findings identify circulating GZMK as an independent correlate of SLE clinical activity and characterize a recurrent GZMK-enriched CD8 + memory/Tem cell program across peripheral blood and affected tissues that is associated with B-cell dysregulation and plasma-cell-related immune abnormalities.
Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by systemic immune activation and multi-organ inflammation. Granzyme K (GZMK), a serine protease predominantly expressed by CD8
+
T cells and natural killer cells, has emerging non-cytotoxic inflammatory functions, but its relevance to SLE remains incompletely defined. In this study, we conducted investigations using plasma and tissue analyses, single-cell RNA sequencing, proteomics, multiplex immunofluorescence, an animal model, and primary human B cell experiments. Plasma GZMK was increased in patients with SLE and was associated with clinical disease activity. Integrated multi-tissue single cell analysis identified preferential GZMK enrichment in CD8
+
effector memory T (Tem) cells and a higher relative abundance of this compartment in SLE, while proteomic profiling and multiplex immunofluorescence provided protein and tissue level evidence for a GZMK-enriched CD8
+
memory T cell population. Cell–cell communication analysis suggested enhanced predicted communication between Tem and B lineage cells, and circulating GZMK was further associated with a plasma cell-like population. In two murine models, PPACK, which can inhibit GZMK catalytic activity but is not GZMK selective, attenuated lupus associated inflammatory phenotypes and partially normalized altered splenic B cell composition.
In vitro
experiments showed that active recombinant GZMK augmented plasma-cell-associated phenotypic and transcriptional responses under B cell expansion conditions. Collectively, these findings identify circulating GZMK as an independent correlate of SLE clinical activity and characterize a recurrent GZMK-enriched CD8
+
memory/Tem cell program across peripheral blood and affected tissues that is associated with B-cell dysregulation and plasma-cell-related immune abnormalities.
The spectrum of T-cell abnormalities in SLE is synthesized and it is proposed that these phenotypes arise from four interacting layers of dysregulation: extracellular cues including cytokine and non-cytokine mediators and altered antigen presentation, T-cell receptor (TCR) and co-stimulatory signaling, immunometabolic...
B cell IFITM2 expression is closely associated with disease activity in SLE and may serve as a potential biomarker to improve the discriminatory performance of anti-dsDNA testing, suggesting that combined assessment of IFITM2 and UTP may help reflect renal status in patients with SLE.
Bin Wen, Xiao-Cui Wang, Xue-Mei Duan et al.· Biomedicines· 0 citations
OBJECTIVE
Tissue-resident memory T (TRM) cells have been implicated in organ-specific immune pathology; however, the pathological relevance of TRM-like CD8+ T cells in systemic lupus erythematosus (SLE) remains unclear. We investigated their differentiation mechanisms and pathological significance in SLE, including ass...
Yuya Fujita, Kaoru Yamagata, S. Kubo et al.· Arthritis & Rheumatology· 0 citations
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease driven by loss of immune tolerance, dysregulated nucleic acid sensing and cytokine signaling, abnormal B- and T-cell activation, persistent autoantibody production, and impaired clearance of immune cells and debris. These interconnected abnormalit...
Yu-Rin Kim, E. Yeo, I. Kang· Current Issues in Molecular...· 0 citations
Chronic active Epstein-Barr virus disease (CAEBV) is a rare EBV-associated T/NK-cell lymphoproliferative disorder characterized by persistent viral infection, systemic inflammation, and highly variable clinical courses. Patients may develop HLH-like hyperinflammation, severe organ involvement, lymphoma transformati...
Yue Cao, Zhe Zhou, Sheng-Lei Yu et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.